Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170008/S056

EluNIR Ridaforolimus Eluting Coronary Stent System

Medinol, Ltd. · Decision date Oct 2, 2025

FDA DECISIONP170008/S056

What did the FDA approve?

FDA records P170008/S056 as a supplement to PMA P170008, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Oct 2, 2025.

FDA approval order statement

a sampling plan that reduces sample size of the incoming inspections for raw materials and components of the EluNIR-PERL Ridaforolimus Eluting Coronary Stent System
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 2, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170008/S056
Regulatory pathway
PMA supplement
Applicant
Medinol, Ltd.
Product code
NIQ
Decision code
APPR
Decision date
Oct 2, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Applicant
Medinol, Ltd.
Product code
NIQ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170008/S056 received

    Application receipt date recorded by FDA.

  2. P170008/S059 · Related supplement

    EluNIR-PERL Ridaforolimus Eluting Coronary Stent System

  3. P170008/S060 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  4. P170008/S056 · FDA decision

    135 Review Track For 30-Day Notice

  5. P170008/S061 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  6. P170008/S062 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  7. P170008/S064 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

Timeline entries are records held by MedtechLedger for P170008. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170008

Product / regulatory recordCompanyPathwayDecision dateSource
Medinol, Ltd.PMA supplementAug 7, 2025FDA
Medinol, Ltd.PMA supplementAug 15, 2025FDA
Medinol, Ltd.PMA supplementFeb 4, 2026FDA
Medinol, Ltd.PMA supplementMar 26, 2026FDA
Medinol, Ltd.PMA supplementAug 6, 2026FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medinol, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Kiryat Atidim, Bldg. 8, P.O.B. 58165, Tel Aviv, 6158101

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records